PAD - Prescribing Advisory Database
PLEASE NOTE : This is a development system.

For Surrey PAD, please go to https://surreyccg.res-systems.net/PAD.

You are here : Home > PAD Profile : Cabergoline - Hyperprolactinaemia

PAD Profile : Cabergoline - Hyperprolactinaemia Important

Keywords :
Hyperprolactinaemic disorders
Brand Names Include :
Dostinex
Important Information :
Initiation and supply of at least one month of treatment before transfer of prescribing to primary care. Monitoring remains the responsibility of secondary care in line with position statement of the British Society of Echocardiography, the British Heart Valve Society and the Society for Endocrinology. https://pubmed.ncbi.nlm.nih.gov/30818417/

Traffic Light Status

Status 1 of 1.

Status :
Blue
Preferred
Formulations :
  • Tablets
Trust Alignment :
Primary Care
ASPH
RSFT
SASH
SABP
Links :
Comments :
No comments returned.
Documents :

Guidelines

No guidelines returned.

Other Drugs

Other Indications

Additional Documents

Committee Recommendations

Date
Committee Name
Narrative
04 September 2024
Surrey Heartlands Integrated Care System Area Prescribing Committee (APC)

The Surrey Heartlands Integrated Care System Area Prescribing Committee have agreed the following place in therapy for cabergoline and bromocriptine:

For the treatment of hyperprolactinaemic disorders

  • BLUE traffic light classification for initiation by specialists for 1 month before transfer of prescribing responsibilities to primary care
  • Cabergoline 1st line & Bromocriptine 2nd line

For the treatment of drug induced hyperprolactinaemia

  • 1st line - select alternative medicine (to remove cause of drug-induced effect)
  • Non-Formulary for cabergoline and bromocriptine

Suppression of lactation

  • RED traffic light classification for cabergoline - as treatment should be part of obstetric care where necessary
  • Non-Formulary for bromocriptine

Associated BNF Codes

06. Endocrine System
06.07.01. Bromocriptine and other dopaminergic drugs
This site uses its own and third party cookies to function properly and to improve performance, to maintain the session and to personalise user experience, as well as to obtain anonymous statistics about the use of the website. Visit our Privacy and Cookie Policy for more information on our data collection practices. By clicking 'Accept' you agree to our use of cookies for the purposes listed.
Learn More